Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials.

Statin use has been linked to reduced mortality in several cancers, including CLL.

他汀类药物的使用已与包括CLL在内的几种癌症的死亡率降低相关联。

However, their concomitant use with targeted therapies such as ibrutinib remains unexplored.

然而，它们与靶向治疗药物如伊布替尼的联合使用尚未被探索。

This study investigates the association of statin use with survival and adverse eventoutcomes in patients with CLL/SLL initiating contemporary treatment regimens, including ibrutinib.

本研究调查了他汀类药物使用与接受包括伊布替尼在内的现代治疗方案的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者生存和不良事件结果之间的关联。

Individual participant data from 4 randomized trials-RESONATE, RESONATE-2, iLLUMINATE, and HELIOS-were used.

使用了4项随机试验的个别参与者数据-RESONATE、RESONATE-2、iLLUMINATE和HELIOS。

Associations between baseline statin use and treatment outcomes were examined using Cox proportional hazards models for overall survival(OS), progression-free survival(PFS), and cancer-specific survival (CCS), and logistic regression models for grade ≥3 adverse effects.

使用Cox比例风险模型评估基线他汀类药物使用与总生存（OS）、无进展生存（PFS）和癌症特异性生存（CCS）之间的关联，以及使用逻辑回归模型评估≥3级不良反应。

Analyses were adjusted for age, sex, weight, Eastern Cooperative Oncology Group performance status, disease diagnosis, bulky disease (≥5 cm), time since diagnosis, comorbidity count, and the use of beta-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and diuretics.

分析调整了年龄、性别、体重、东协作肿瘤组表现状态、疾病诊断、巨大病变（≥5厘米）、诊断时间、合并症计数以及使用β受体阻滞剂、钙通道阻滞剂、血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂和利尿剂的情况。

Of 1467 patients, 424 (29%) were using statins.

在1467名患者中，有424名（29%）正在使用他汀类药物。

Statin use was significantly associated with improved OS (adjusted hazard ratio[aHR] 0.62 [95% CI, 0.48‑0.79], P < 0.001), PFS (aHR 0.74 [95% CI, 0.62-0.89], P = 0.001), and CCS (aHR 0.39 [95% CI, 0.22-0.70], P = 0.001).

他汀类药物的使用与总生存期（调整后风险比[aHR] 0.62 [95% 置信区间, 0.48‑0.79], P < 0.001）、无进展生存期（aHR 0.74 [95% 置信区间, 0.62-0.89], P = 0.001）和癌症特异性生存期（aHR 0.39 [95% 置信区间, 0.22-0.70], P = 0.001）的显著改善显著相关。

Findings were consistent across ibrutinib vs nonibrutinib treatment arms and CLL vs SLL diagnosis.

在伊布替尼与非伊布替尼治疗组以及慢性淋巴细胞性白血病（CLL）与小淋巴细胞性淋巴瘤（SLL）诊断之间，研究结果保持一致。

No significant association with grade ≥3 adverse effects was observed.

未观察到与3级或更高级别不良反应有显著关联。

Statin use was identified as an independent positive prognostic factor in patients with CLL/SLL, irrespective of the treatment employed.

在CLL/SLL患者中，无论采用何种治疗，他汀类药物使用被确定为一个独立的积极预后因素。

Further research is needed to validate these results and explore the underlying impacts of statins in CLL/SLL.

需要进一步的研究来验证这些结果，并探索他汀类药物在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中的潜在影响。

These trials were registered at www.ClinicalTrials.gov as #NCT01578707, #NCT01722487, #NCT02264574, and #NCT01611090.

这些试验已在www.ClinicalTrials.gov上注册，注册号为#NCT01578707、#NCT01722487、#NCT02264574和#NCT01611090。